Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma.

Autor: El Zarif T; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Semaan K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Eid M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Garinet S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Davidsohn MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sahgal P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Fortunato B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Canniff J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nassar AH; Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Abou Alaiwi S; Section of Cardiology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Bakouny Z; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lakshminarayanan G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Savignano H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lyons K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Matar S; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Ali A; Department of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA., Saad E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Saliby RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cordeiro P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., El Ahmar N; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Laimon YN; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Labaki C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA., Shah V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Freeman D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., O'Toole J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lee GM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hwang J; Department of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA., Pomerantz M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Signoretti S; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Xie W; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Viswanathan SR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Braun DA; Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: matthew_freedman@dfci.harvard.edu., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA. Electronic address: sylvan_baca@dfci.harvard.edu.

Publikováno v: Cell reports [Cell Rep] 2024 Jun 25; Vol. 43 (6), pp. 114350. Date of Electronic Publication: 2024 Jun 12.

The Role of the Pathologist in Renal Cell Carcinoma Management.

Autor: Matar S; Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA., El Ahmar N; Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA., Laimon YN; Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA., Ghandour F; Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA., Signoretti S; Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Merkin Building, 415 Main Street, Cambridge, MA 02142, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: ssignoretti@bwh.harvard.edu.

Publikováno v: Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2023 Oct; Vol. 37 (5), pp. 849-862. Date of Electronic Publication: 2023 May 29.

Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment.

Autor: Albertí-Valls, Manel¹ (AUTHOR) manel.alberti@udl.cat, Olave, Sara² (AUTHOR), Olomí, Anna³ (AUTHOR), Macià, Anna¹ (AUTHOR), Eritja, Núria^1,2 (AUTHOR) manel.alberti@udl.cat

Publikováno v: Cancers. Dec2024, Vol. 16 Issue 23, p3918. 26p.

Evidence for the cooking of fish 780,000 years ago at Gesher Benot Ya'aqov, Israel.

Autor: Zohar, Irit, Alperson-Afil, Nira, Goren-Inbar, Naama, Prévost, Marion, Tütken, Thomas, Sisma-Ventura, Guy, Hershkovitz, Israel, Najorka, Jens

Publikováno v: Nature Ecology & Evolution; Dec2022, Vol. 6 Issue 12, p2016-2028, 13p

Palaeopathology at the Khan-el-Ahmar site: Health and disease in a Byzantine monastery in the Judean Desert, Israel.

Autor: Hershkovitz, I., Yakar, R., Taitz, C., Eshed, V., Wish-Baratz, S., Pinhasov, A., Ring, B.

Publikováno v: International Journal of Osteoarchaeology; Mar1995, Vol. 5 Issue 1, p61-76, 16p